RETRACTED: si-PDGFR-Loaded Exosomes Suppress the Progression of Glioma by Inhibiting the Oxidative Associated PI3K/Akt/EZH2 Signaling Pathway (Retracted Article)

This study investigated the possibility of exosomes loaded with si-PDGFR beta ability to suppress the progression of glioma. Common gliomas develop from neuroglial progenitor cells. Many variables affect the survival rate and occurrence of gliomas. Understanding oxidative stress processes and creating new, efficient treatments are crucial because oxidative stress is linked to the development of brain tumors. For this purpose, selected clinical samples were subjected to various tests like quantitative real-time PCR, Cignal Finder RTK signaling 7-pathway reporter array analysis, CCK-8 analysis, flow cytometry, and immunoblotting. Here, we demonstrated that PDGFR beta expression was increased in glioma patients. Following that, cell-derived exosomes were extracted and collected and traced in vivo, and selected tissue samples were subjected to immunohistochemical analysis. The results indicated that the knockdown of PDGFR beta (si-PDGFR beta) inhibited the proliferation of glioma cells. Besides this, si-PDGFR beta-loaded exosomes induced a similar antitumor effect in glioma cells. The anticancer effect of si-PDGFR beta-loaded exosomes was mediated by the inactivation of the PI3K/Akt/EZH2 pathway. Finally, we verified that this exosome delivery system, si-PDGFR beta-loaded exosomes, had robust targeting and no associated toxicity. In conclusion, the study confirmed that si-PDGFR beta-loaded exosomes inhibit glioma progression via inactivating the PI3K/Akt/EZH2 signaling pathway.